Belluscura PLC on Tuesday withdrew its previous financial guidance for 2025, citing to the US imposition of tariffs on imports.

The London-based medical device developer highlighted that a ‘significant proportion’ of its portable oxygen concentrators, raw materials and component parts are made in China. They are facing a 54% tariff when imported to the US.

The firm expects to make a further announcement once it has been able to better assess the situation.

Belluscura shares were down 44% to 0.70 pence each on Tuesday morning in London.

Copyright 2025 Alliance News Ltd. All Rights Reserved.